INTS - NASDAQ
Intensity Therapeutics, Inc.
$1.32
+3.9E+2%Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
At a Glance
Live SnapshotIntensity Therapeutics, Inc. Management Team
Mr. Joseph Talamo CPA, M.B.A.
Chief Financial Officer
Compensation
$416,930
Mr. Brian Schwartz M.D.
Executive Vice President of Clinical Development
Mr. James M. Ahlers
Executive Vice President of Corporate Finance
Compensation
$75,088
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Founder, President, Chief Executive Officer & Chairman of the Board
Compensation
$597,007
Mr. John Wesolowski CPA, M.B.A.
Principal Accounting Officer & Controller
Compensation
$260,898
Intensity Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $22K worth of INTS shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
83.9K
21.90K
0
0.00
+22K
+$22K
Top Buyers
Wesolowski John M
Officer: Principal Accounting Officer
$18K
Talamo Joseph
Officer: Chief Financial Officer
$4K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $22K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
INTS - Filing history and reports
No SEC filings available for INTS
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.